Baxter begins enrolment for Phase III trial of citrate anticoagulant and renal replacement solution combination

US healthcare company Baxter has begun enrolment for its Phase III clinical trial of a drug that is a combination of citrate anticoagulant and renal replacement solution to treat acute kidney-injury patients receiving continuous renal replacement the …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news